CAS: 1346233-68-8

3,5-Dichloro-N-[[(1',5',6-exo,6')-3-(3,3-dimethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]benzamide is a drug that binds to calcium and chondroitin sulfate in the extracellular environment of cancer cells. 3,5-Dichloro-N-[(1',5',6'-exo,6')-(3,3'-dimethylbutyl)-3'-azabicyclo[3.1.0]hexane]-2,2'-dicarboxylic acid (DCA) has been shown to selectively kill brain tumor cells over normal brain cells in vitro by inhibiting protein synthesis and inducing cell death through a multistep process. DCA also inhibits the production of antigens that are involved in the interaction between T lymph

ML218 is an inhibitor of T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3).ML218 inhibits the synaptic activity of subthalamic nucleus (STN) neurons.

Applications This compound, referred to as ML218, is a centrally active calcium channel inhibitor with potential applications to treatment of pain, epilepsy and neurological disorders through further study. References Xiang, Z. et al.: ACS Chem. Neurosci., 2, 730 (2011);